Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Bruno Scheller
Optimising bifurcation PCI with drug-coated balloons and angiography-derived physiology
Monday 30 November 2026 | 4:00pm (UTC+1) Participate in this live event Register with your My PCR account, add it to your calendar and receive automatic reminders.
Periarterial nerves along the human hepatic artery: anatomical determinants for cardiometabolic neuromodulation
Abstract Preclinical and early clinical studies suggest that catheter-based hepatic artery denervation is a neuromodulation strategy with potential relevance for blood pressure and cardiometabolic regulation, but high-resolution human data on nerves along the hepatic arterial course remain limited. This study aimed to characterize periarterial nerves along the human hepatic artery and to identify anatomically favorable target regions for catheter-based denervation.
Drug-coated balloons: past, present and future
Drug-coated balloons: past, present and future Monday 21 September 2026 | 11:30am (UTC+2)
The next frontier of DCB is to simplify complexity
VIDEO Objectives: Join this webinar if you want to: Understand the role and potential advantages of DCBs in complex patients and lesions Discuss practical considerations for lesion preparation and post-DCB result assessment to optimize outcomes Participate in case-based discussions of complex cases with angiographic follow-up Speakers: Interventional cardiologist / Cardiologist Hospital Clínico San Carlos - Madrid, Spain Interventional cardiologist / Cardiologist Saarland University -...
Paclitaxel-coated balloon treatment is associated with sympathetic coronary denervation in a porcine model
Abstract Drug-coated balloon (DCB) therapy promotes beneficial vascular remodeling after percutaneous coronary intervention. However, its mechanisms remain elusive. Given paclitaxel’s neurotoxicity, the effects of paclitaxel (PTX)-DCB treatment on periarterial innervation are unknown. This study assessed the impact of PTX-DCB on periarterial innervation in porcine coronary arteries.
Menos stents para el IAMCEST: ¿está listo el balón farmacoactivo para su gran momento?: Comentario editorial
Ayuda Buscar en la ayuda Buscar en la ayuda Menos stents para el IAMCEST: ¿está listo el balón farmacoactivo para su gran momento?: Comentario editorial [1] Clinical and Experimental Interventional Cardiology, University of Saarland, Hamburgo/Sarre, Alemania Localización: Revista española de cardiología, ISSN 0300-8932, Vol. 79, Nº. 2, 2026, págs. 106-107 Idioma: español Títulos paralelos: Fewer stents for STEMI. Are DCBs ready for prime time? Enlaces Texto completo
Indications for Use of Drug-Coated Balloons in Coronary Intervention: Academic Research Consortium Position Statement
JACC Journals › JACC › Archives › Vol. 86 No. 15 JACC State-of-the-Art Review : JACC Volume 86, Number 15 Get full access to this article View all available purchase options and get full access to this article. Supplementary Material Supplemental Material (mmc1.docx) References 1. Scheller B., Speck U., Abramjuk C., Bernhardt U., Bohm M., Nickenig G. Paclitaxel balloon coating, a novel method for prevention and therapy of restenosis. Circulation. 2004;110:810-814. 2.
Cost‐Effectiveness of Drug‐Coated Balloons in the Treatment of Coronary Small Vessel Disease: A Report From the BASKET‐SMALL 2 Randomized Controlled Trial | Journal of the American Heart Association
Research Article Open Access Journal of the American Heart Association Nonstandard Abbreviations and Acronyms DCB drug‐coated balloon DES drug‐eluting stent EES everolimus‐eluting stent ICER incremental cost‐effectiveness ratio MACE major adverse cardiac events Clinical Perspective • Drug‐coated balloons and drug‐eluting stents are associated with similar costs in the treatment of small vessel coronary artery disease.
Frontiers | Safety aspects of de novo DCB-only PCI—a practical checklist and a simplified revised dissection classification
Background Drug-coated balloon (DCB)-only percutaneous coronary intervention (PCI) is a rapidly expanding area of coronary intervention. However, to protect patients while encouraging increased uptake of appropriate DCB use, it is vital to have a meticulous procedural technique. It is imperative that the early safety of this new stentless PCI approach is well documented.
Drug-coated balloons as a first choice for patients with de novo lesions: pros and cons
Participate in this live event Register with your My PCR account, add it to your calendar and receive automatic reminders.
Paclitaxel‐coated versus sirolimus‐coated balloon angioplasty for coronary artery disease: A systematic review and meta‐analysis
CONFLICT OF INTEREST STATEMENT Prof. Scheller is a shareholder of InnoRa GmbH, Berlin, Germany, and received lecture honoraria from B. Braun and Medtronic. Dr. Kandzari receives institutional research/grant support from Ablative Solutions, Biotronik, Orbus Neich, Medtronic, Supira Medical, and Teleflex, and personal consulting honoraria from Medtronic. Prof.
Bioresorbable scaffolds - new evidence and clinical applications
Participate in this live event Register with your My PCR account, add it to your calendar and receive automatic reminders. Please log into your MyPCR account before proceeding Join us if you want to: Revisit the concept and new technology of BRS Learn about new preclinical and clinical evidence on BRS Discuss potential clinical applications of BRS today Do you know Top Companions? As a healthcare practitioner, you can obtain points each time you participate in PCR activities.
Why and when to use DCB?
Participate in this live event Register with your My PCR account, add it to your calendar and receive automatic reminders.
Drug‐coated balloon angioplasty is a well‐established treatment and in everyday use in cathlabs worldwide
REPLY Drug-coated balloon angioplasty is a well-established treatment and in everyday use in cathlabs worldwide Tuomas T. Rissanen, Corresponding Author Tuomas T. Rissanen Heart Center, North Karelia Central Hospital, Joensuu, Finland Correspondence Tuomas T. Rissanen, Heart Center, North Karelia Central Hospital, Joensuu, Finland. Email: tuomas.rissanen@siunsote.fi Search for more papers by this authorFranz X. Kleber, Franz X.
JCDD | Free Full-Text | Impact of Insulin-Treated Compared to Non-Insulin-Treated Diabetes Mellitus on Outcome of Percutaneous Coronary Intervention with Drug-Coated Balloons versus Drug-Eluting Stents in De Novo Coronary Artery Disease: The Randomized BA
Altmetric share Share announcement Help format_quote Cite thumb_up ... Endorse textsms ... Comment Need Help? Support Find support for a specific problem in the support section of our website. Get Support Feedback Please let us know what you think of our products and services. Give Feedback Information Visit our dedicated information section to learn more about MDPI.
DCB in PCI: Adjunctive Therapy or Standard of Care?
Key Learning Objectives To discuss the origins and science behind the DCB technology, its current and potential areas of application in various clinical scenarios, and emphasize the benefits of DCB technology vs DES and Paclitaxel vs Limus. To emphasize the importance of vessel preparation, algorithms of optimal therapy delivery and criteria used for immediate results evaluation.
RADIANCE-HTN: 6Mo Outcomes of RDN Vs a Sham Procedure for Resistant Hypertension
Video RADIANCE-HTN: 6Mo Outcomes of RDN Vs a Sham Procedure for Resistant Hypertension Published: 11 Nov 2021 Views: 14 Likes: 0 In this short summary interview, Dr. Ajay Kirtane (Columbia University Medical Center, US) shares the six-month outcomes of a randomized trial of renal denervation (RDN) versus a sham procedure for resistant hypertension.
What to Expect at Complex PCI 2021
Video What to Expect at Complex PCI 2021 Published: 09 Nov 2021 Views: 40 Likes: 0 In this video, USC Editor-in Chief Dr Bill Gogas discusses the upcoming 2021 Complex PCI event with Dr Duk-Woo Park (Asan Medical Center, Seoul, KR). Dr Park provides an overview of what we can expect to see at Complex PCI this year. Videography: Oliver Miles
TRISCEND II: 6Mo Outcomes Show TR Reduction in Majority of Patients
Video TRISCEND II: 6Mo Outcomes Show TR Reduction in Majority of Patients Published: 06 Nov 2021 Views: 3 Likes: 0 Dr Susheel Kodali (Columbia University Medical Center, New York, NY, US) discusses the six-month outcomes of the TRISCEND II Pivotal Trial. Originally presented at TCT 2021, this is a randomized multicenter controlled trial aiming to evaluate the safety and effectiveness of the EVOQUE tricuspid valve replacement system.
Impact of Diabetes on Outcome With Drug-Coated Balloons Versus Drug-Eluting Stents: The BASKET-SMALL 2 Trial
Abstract Objectives The study sought to evaluate the impact of diabetes mellitus on 3-year clinical outcome in patients undergoing drug-coated balloon (DCB) or drug-eluting stent (DES) treatment for de novo lesions. Background For treatment of de novo coronary small vessel disease, DCBs are noninferior to DES.
Late lumen enlargement after treatment of de-novo lesions with drug coated balloon catheters - Glagov effect or plaque regression?
Percutaneous transluminal angioplasty [ ] and stent implantation [ 2 Sigwart U. Puel J. Mirkovitch V. Joffre F. Kappenberger L. Intravascular stents to prevent occlusion and restenosis after transluminal angioplasty. N. Engl. J. Med. 1987; 316 : 701-706 ] became the standard of care in the majority of treatments of stenotic and occluded arteries. In addition to an improved pharmacological concomitant therapy in the form of dual platelet inhibition [ 3 Colombo A. Hall P. Nakamura S. et al.
Drug-coated balloons for patients with increased risk of bleeding
1 Schömig A Neumann FJ Kastrati A et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med. 1996; 334 : 1084-1089 However, dual antiplatelet therapy might increase the incidence of bleeding events in the presence of further risk factors.
Hydration and contrast-induced kidney injury
We read with interest the randomised trial by Estelle Nijssen and colleagues (April 1, p 1312).1 Nijssen and colleagues found no hydration to be non-inferior to prophylactic hydration to protect renal function from intravascular iodinated contrast media.Because the trial focuses on patients with only moderate chronic kidney disease during elective procedures, it is possible that these patients do not benefit from hydration.
Bruno Scheller | Radcliffe Cardiology
Dr Bruno Scheller studied medicine at the University of Saarland, Germany, from 1988 til 1994. Since 1994 he has been working as a physician at the clinic for internal medicine III,, University Hospital of Saarland, Homburg/Saar, Germany, where he is a consultant for internal medicine, cardiology, and intensive care. He is a full professor for Clinical and Experimental Interventional Cardiology at the Medical School of the University.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Bruno
Contact Bruno, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack